An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
STONY BROOK, N.Y.--(BUSINESS WIRE)--
Applied DNA Sciences, Inc. (NASDAQ: APDN) (the “Company”), a leader in PCR-based DNA technologies, today announced that it plans to release its fiscal 2022 fourth quarter and year-end financial results after the market close on Wednesday, December 14, 2022.
The Company’s management will host a conference call with investors and covering analysts starting at 4:30 pm ET that same day. On the call, Chief Financial Officer Beth Jantzen and President and CEO Dr. James A. Hayward will discuss the Company’s quarterly financial performance and recent accomplishments, followed by a question-and-answer session.
To access the conference call:
U.S. callers should dial 1-844-887-9402, and international callers should dial +1-412-317-6798 approximately five minutes before the call begins.
Participants should ask to be connected to the Applied DNA Financial Results conference call.
You can listen to the call and view the accompanying exhibits on Applied DNA’s investor relations website at https://investors.adnas.com/news-events/company-events/ at the scheduled time. A webcast replay of the call will also be available on the investor relations website approximately one hour after the end of the call.
About Applied DNA Sciences
Applied DNA Sciences is a biotechnology company developing technologies to produce and detect deoxyribonucleic acid ("DNA"). Using the polymerase chain reaction ("PCR") to enable both the production and detection of DNA, we operate in three primary business markets: (i) the manufacture of DNA for use in nucleic acid-based therapeutics; (ii) the detection of DNA in molecular diagnostics testing services; and (iii) the manufacture and detection of DNA for industrial supply chain security services.
The Company's common stock is listed on NASDAQ under the ticker symbol 'APDN,' and its publicly traded warrants are listed on OTC under the ticker symbol 'APPDW.'
we keep life real and safe by providing botanical-dna based security and authentication solutions and services that protect assets, products, brands, supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.
